{
    "clinical_study": {
        "@rank": "1417", 
        "acronym": "RBL", 
        "arm_group": {
            "arm_group_label": "Patients with Burkitt's Lymphoma", 
            "description": "should be diagnosed pathologically by WHO 2008 criteria"
        }, 
        "brief_summary": {
            "textblock": "This retrospective study is aimed at evaluating the safety and efficacy of\n      rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or\n      high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large\n      B-cell lymphoma and BL."
        }, 
        "brief_title": "Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Burkitt's Lymphoma", 
            "High-grade B-cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "Inclusion criteria\n\n        1. pathologically confirmed BL or BL-U by WHO 2008 criteria\n\n        2. age >20 yrs\n\n        3. received rituximab+chemotherapy as first-line treatment\n\n        4. with measurable or evaluable lesion\n\n        5. with complete set of clinical and laboratory data for the analysis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma,\n             unclassifiable, with features intermediate between diffuse large B-cell lymphoma and\n             BL (BL-U) by WHO 2008 criteria\n\n          2. age >20 yrs\n\n          3. received rituximab+chemotherapy as first-line treatment\n\n          4. with measurable or evaluable lesion\n\n        Exclusion Criteria:\n\n        1. patients with BL or BL-U previously treated with rituximab"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "patients who were treated with Burkitt's or Burkitt-like high-grade B-cell lymphoma in\n        Republic of Korea"
            }
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809600", 
            "org_study_id": "CISL-1203"
        }, 
        "intervention": {
            "arm_group_label": "Patients with Burkitt's Lymphoma", 
            "intervention_name": "No intervention (observational study)", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 11, 2013", 
        "location": {
            "contact": {
                "email": "alertjun@hanmail.net", 
                "last_name": "Junshik Hong, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of", 
                    "zip": "405-760"
                }, 
                "name": "Gachon University Gil Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL", 
        "overall_contact": {
            "email": "alertjun@hanmail.net", 
            "last_name": "Junshik Hong, MD", 
            "phone": "+82-10-3395-8656"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center, Seoul, Korea", 
            "last_name": "Suk Jin Kim, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death)", 
            "measure": "Event-free survival", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809600"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Gachon University Gil Medical Center", 
            "investigator_full_name": "Junshik Hong", 
            "investigator_title": "Assistant Professor, Department of Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "treatment response will be evaluated according to the Revised criteria for malignant lymphoma (Journal of Clinical Oncology 25:579-586)", 
                "measure": "complete response rate", 
                "safety_issue": "No", 
                "time_frame": "1-year"
            }, 
            {
                "description": "Overall survival is defined as the time from treatment initiation until death as a result of any cause", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "1-year"
            }, 
            {
                "description": "toxicities will be graded according to Common Toxicity Criteria for Adverse Events (CTCAE) V.4.0. Hematologic toxicities planned to evaluated were; anemia (by hemoglobin), absolute neutrophil count, and platelet count", 
                "measure": "Grade 4 hematologic toxicities", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "source": "Gachon University Gil Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gachon University Gil Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}